ABCSG 16/S.A.L.S.A. Summary

Prospective, randomized, open-label, multi-center, phase-II-study evaluating the effect of a secondary adjuvant endocrine therapy with anastrozole for 2 years vs. 5 years in patients with hormone-receptor-positive breast cancer after 5 years prior adjuvant endocrine therapy.

Recruiting period: 01/2004-30.06.2010
Coordinating investigator: Gnant, Michael; Vienna
Sample size: 3.500
(Click to enlarge)
ABCSG-16 Design